1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Markets for Drug Repurposing

Global Markets for Drug Repurposing

  • January 2016
  • -
  • BCC Research
  • -
  • 103 pages

This BCC Research report provides an overview of the current and future global market for drug repurposing. Includes forecast through 2020.

Use this report to:

Analyze the global market for repurposed drugs by application, by usage, and used orally or intravenously.
Analyze the various trends, mergers and acquisitions within the repurposed drug market.
Gain information about the regulatory environment, technologies, market projections and market shares for repurposed drug market.
Gain information about the usage of repurposed drugs in central nervous disorders, cardiovascular disorders, oncology, metabolic, autoimmune, and other disorders.

Highlights

The global market for drug repurposing will grow from nearly $24.4 billion in 2015 to nearly $31.3 billion by 2020, with a compound annual growth rate (CAGR) of 5.1% for the period of 2015-2020.
The U.S. dominated the drug repurposing market and should reach approximately $13.7 in 2015 and close to $17.9 billion by 2020, rising at a CAGR of 5.4%.
The non-U.S. market is expected to increase from $ 10.6 billion in 2015 to nearly $13.4 billion by 2020 with a CAGR of 4.7%.

STUDY GOALS AND OBJECTIVES

Drug repurposing is the one of the major revolutions taking place in the pharmaceutical industry. Advancements in technologies such as bioinformatics, genomics and proteomics are making drug repositioning possible. Drug
repositioning/repurposing reduces development costs and time, improves return on investment and also facilitates the rescue of previously failed compounds.

BCC Research’s goal in conducting this study is to provide an overview of the current and future global market for drug repurposing. The key objective is to present a comprehensive analysis and outline the future direction of drug repurposing as an important change in the process of drug development. The report discusses market
improvements, setbacks and demands and compares the use of this type of development.

Through a detailed analysis of the structure of the drug repurposing industry, the revenues have been broken down intoU.S.and non-U.S. sectors. Sales figures are estimated for the five-year period from 2015 through 2020.
Applications for drug repurposing are also discussed, with an emphasis on the use of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.

SCOPE OF THE REPORT

This report provides a global overview of drug repurposing, also known as repositioning or reprofiling, including the techniques and applications in various therapies. The report deals with the global market for repurposed drugs in three main areas: market by application of repurposed drugs, by usage of repurposed drugs and by application
site (i.e., whether they are used orally or intravenously). The application area is divided into types of disorders (i.e., repurposed drugs in central nervous disorders, cardiovascular disorders, oncology, metabolic, autoimmune and other disorders).

Market by usage is analyzed on the basis that repurposed drugs are used alone in single therapy or used in combination with other drugs.

Excluded from this report are drugs that are not yet approved as repurposed drugs.

BCC Research analyzes the market and its applications, regulatory environment, technologies involved, market projections and market shares. The market is mainly divided into theU.S.and the rest of the world (ROW).

Also included in the report are relevant patent analysis and comprehensive profiles of the leading companies in the drug repurposing market. The key players are Novartis AG, Abbott Healthcare, Pfizer Inc., Johnson & Johnson and Hoffmann-La Roche. Other significant players are the generic drug manufacturers such as Sandoz, Mylan Inc., and Teva Pharmaceuticals. The chapter on company profiles also includes even core drug
repurposing companies such as SOM Biotech, Biovista Inc. and Sosei Group Ltd.

Table Of Contents

Global Markets for Drug Repurposing
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
INTENDED AUDIENCE 2
SCOPE OF THE REPORT 3
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 5
CHAPTER 2 EXECUTIVE SUMMARY 7
SUMMARY TABLE GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION,
THROUGH 2020 ($ MILLIONS) 8
SUMMARY FIGURE GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION,
2013-2020 ($ MILLIONS) 8
CHAPTER 3 OVERVIEW 10
DEFINITIONS 10
DRUG 10
CHEMICAL DRUG 10
BIOLOGICAL DRUG 10
DRUG REPURPOSING 10
ACTIVE PHARMACEUTICAL INGREDIENT (API) 10
DRUG DEVELOPMENT 10
PHARMACEUTICAL DRUGS 10
CLASSIFICATION OF DRUGS 11
CHEMICAL OR SMALL MOLECULE DRUGS 11
BIOLOGIC DRUGS 11
TABLE 1 COMPARISON OF CHEMICALLY SYNTHESIZED DRUGS AND BIOLOGIC
DRUGS 12
HISTORY OF PHARMACEUTICAL DRUGS 13
TABLE 2 EVOLUTION OF DRUG PRODUCTS 13
DRUG DEVELOPMENT PROCESS 14
TARGET SELECTION/IDENTIFICATION 14
TECHNIQUES FOR TARGET IDENTIFICATION 15
TARGET VALIDATION 15
DRUG DISCOVERY/LEAD DISCOVERY 15
INITIAL SAFETY TESTS 16
LEAD OPTIMIZATION 16
PRECLINICAL TESTING 16
INVESTIGATIONAL NEW DRUG APPLICATION AND SAFETY 16
CLINICAL TRIALS 17
Phase I Clinical Trials 17
Phase II Clinical Trials 17
Phase III Clinical Trials 17
NEW DRUG APPLICATION AND APPROVAL 18
MANUFACTURING 18
PHASE IV TRIALS 18
DRUG REPURPOSING 19
LIPINSKI'S RULE OF 5 (RO5) AND EXTENSIONS 20
DEVELOPMENT OF REPURPOSED DRUGS 20
TABLE 3 DIFFERENCES IN NOVEL DRUG DEVELOPMENT AND DRUG REPURPOSING 21
DRUG REPURPOSING METHODS 21
DRUG/TARGET-BASED 22
DISEASE-BASED 22
APPLICATION AREAS OF DRUG REPURPOSING 22
ADVANTAGES AND LIMITATIONS OF DRUG REPURPOSING 22
ADVANTAGES 23
Safety 23
Time and Cost-Effectiveness 23
High Market and Return Potential 23
Treatment of Rare Diseases 23
LIMITATIONS 24
Dependence on Public Data 24
Lack of Funding Opportunities 24
Lack of Familiarity with Regulatory Procedures 24
COMMON REPOSITIONED DRUGS 25
TABLE 4 COMMON REPOSITIONED DRUGS THAT ARE MARKET APPROVED OR
UNDERGOING RESEARCH 25
CHAPTER 4 REGULATORY ASPECTS 29
TABLE 5 MARKET APPROVALS OF REPURPOSED DRUGS, 2010 TO APRIL 2015 29
RECALLS 30
TABLE 6 RECALLS OF REPURPOSED DRUGS, 2010 TO APRIL 2015 31
SAFETY ALERTS 32
TABLE 7 SAFETY ALERTS FOR REPURPOSED DRUGS 32
CHAPTER 5 TRENDS 35
DRUG REPOSITIONING IN PIPELINE 35
MERGERS AND ACQUISITIONS 36
TABLE 8 MERGERS AND ACQUISITIONS OF MAJOR PHARMACEUTICAL COMPANIES,
2010 TO APRIL 2015 36
CURRENT SITUATION 39
FACTORS AFFECTING DRUG REPURPOSING 39
DRIVERS OF THE MARKET FOR DRUG REPURPOSING 39
Aging Population 39
Increased Prevalence of Chronic Diseases 40
Lifestyle Changes 40
Safety 40
Time and Economic Benefits 40
Advances in Drug Repurposing Methods 40
Treatment of Rare Diseases 41
RESTRAINTS AND CHALLENGES 41
Dependence on Public Data 41
Funding Opportunities 41
Lack of Understanding of Regulatory Issues 41
MARKET OPPORTUNITIES 41
CHAPTER 6 MARKET ANALYSIS 44
INTRODUCTION 44
MARKET BY REGION 45
MARKET REVENUE 45
TABLE 9 GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020
($ MILLIONS) 46
FIGURE 1 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION,
2013-2020 ($ MILLIONS) 46
MARKET SHARE 47
TABLE 10 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%) 47
FIGURE 2 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%) 47
MARKET BY APPLICATION 47
MARKET OVERVIEW 48
MARKET REVENUE 49
TABLE 11 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION, THROUGH
2020 ($ MILLIONS) 50
FIGURE 3 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION,
2013-2020 ($ MILLIONS) 50
MARKET SHARE 51
TABLE 12 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION,
2014 (%) 51
FIGURE 4 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION,
2014 (%) 51
CENTRAL NERVOUS SYSTEM DISORDERS 52
TABLE 13 TYPES OF CENTRAL NERVOUS SYSTEM DISORDERS 52
Market Overview 53
Market Revenue 53
TABLE 14 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CENTRAL
NERVOUS SYSTEM DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 53
FIGURE 5 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CENTRAL
NERVOUS SYSTEM DISORDERS BY REGION, 2013-2020 ($ MILLIONS) 54
CARDIOVASCULAR DISORDERS 54
TABLE 15 TYPES OF CARDIOVASCULAR DISORDERS 55
Market Overview 55
Market Revenue 56
TABLE 16 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR
CARDIOVASCULAR DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 56
FIGURE 6 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR
CARDIOVASCULAR DISORDERS BY REGION, 2013-2020 ($ MILLIONS) 56
ONCOLOGY DISORDERS 57
TABLE 17 TYPES OF CANCER-DEPENDING ON THE TISSUE OF ORIGIN 58
Market Overview 58
Market Revenue 59
TABLE 18 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR ONCOLOGY
DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 60
FIGURE 7 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR
ONCOLOGY DISORDERS BY REGION 2013-2020 ($ MILLIONS) 60
AUTOIMMUNE DISORDERS 60
TABLE 19 TYPES OF AUTOIMMUNE DISEASES 61
Market Overview 62
Market Revenue 63
TABLE 20 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE
DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 63
FIGURE 8 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR
AUTOIMMUNE DISORDERS BY REGION, 2013-2020 ($ MILLIONS) 64
METABOLIC AND OTHER DISORDERS 64
Diabetes 64
Type 1 Diabetes 65
Type 2 Diabetes 65
Gestational Diabetes 65
Osteoporosis 65
Erectile Dysfunction 65
Benign Prostatic Hyperplasia (BPH) 65
Mediterranean Fever 65
Hemolytic Uremia Syndrome 66
Market Overview 66
Market Revenue 66
TABLE 21 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND
OTHER DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 67
FIGURE 9 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND
OTHER DISORDERS BY REGION, 2013-2020 ($ MILLIONS) 67
MARKET ANALYSIS BY USAGE 68
MARKET OVERVIEW 68
MARKET REVENUE 69
TABLE 22 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, THROUGH 2020
($ MILLIONS) 69
FIGURE 10 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, 2013-2020 ($
MILLIONS) 69
MARKET ANALYSIS BY APPLICATION SITE 70
MARKET OVERVIEW 70
MARKET REVENUE 71
TABLE 23 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION SITE
THROUGH 2020 ($ MILLIONS) 72
FIGURE 11 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION
SITE 2013-2020 ($ MILLIONS) 72
CHAPTER 7 INDUSTRY STRUCTURE 74
CENTRAL NERVOUS SYSTEM DISORDERS 74
MARKET LEADERS 74
TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
CENTRAL NERVOUS SYSTEM DISORDERS, 2014 74
MARKET SHARE 75
TABLE 25 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%) 75
FIGURE 12 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF REPURPOSED
DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%) 76
AUTOIMMUNE DISORDERS 76
MARKET LEADERS 76
TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
AUTOIMMUNE DISORDERS, 2014 77
MARKET SHARE 77
TABLE 27 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%) 77
FIGURE 13 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%) 78
ONCOLOGY DISORDERS 78
MARKET LEADERS 78
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
ONCOLOGY DISORDERS, 2014 78
MARKET SHARE 79
TABLE 29 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR ONCOLOGY, 2014 79
FIGURE 14 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR ONCOLOGY, 2014 (%) 79
CARDIOVASCULAR DISORDERS 80
MARKET LEADERS 80
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
CARDIOVASCULAR DISORDERS, 2014 80
MARKET SHARE 80
TABLE 31 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR CARDIOVASCULAR DISORDERS, 2014 81
FIGURE 15 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR CARDIOVASCULAR DISORDERS, 2014 (%) 81
METABOLIC DISORDERS 82
MARKET LEADERS 82
TABLE 32 LEADING MANUFACTURES/SUPPLIERS OF REPURPOSED DRUGS FOR
METABOLIC DISORDERS, 2014 82
MARKET SHARE 82
TABLE 33 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR METABOLIC DISORDERS, 2014 82
FIGURE 16 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR METABOLIC DISORDERS, 2014 (%) 82
OTHER DISORDERS 83
MARKET LEADERS 83
TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
OTHER DISORDERS, 2014 83
MARKET SHARE 84
TABLE 35 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR OTHER DISORDERS, 2014 84
FIGURE 17 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR OTHER DISORDERS, 2014 (%) 84
CHAPTER 8 PATENT ANALYSIS 87
PATENTS BY YEAR 87
TABLE 36 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015 88
FIGURE 18 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015 88
PATENTS BY COMPANY 88
TABLE 37 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015 88
FIGURE 19 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015 89
PATENTS BY COUNTRY 89
TABLE 38 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015 89
FIGURE 20 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015 89
TABLE 39 PATENTS BY COUNTRY, 2010 TO APRIL 2015 (NO/%) 90
FIGURE 21 PATENT SHARES BY COUNTRY, 2010 TO APRIL 2015 (%) 90
PATENTS BY ASSIGNEE 91
TABLE 40 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015 91
FIGURE 22 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015 (NO. OF
PATENTS) 91
CHAPTER 9 COMPANY PROFILES 94
ABBVIE INC. 94
ACTAVIS INC. 94
ALEXION PHARMACEUTICALS INC. 95
APOTEX INC. 95
AUROBINDO PHARMA LTD. 96
BIOGEN IDEC INC. 97
BIOVISTA INC. 97
CELGENE CORP. 98
DR. REDDY'S LABORATORIES LTD. 98
ELI LILLY and CO. 99
GLAXOSMITHKLINE 100
HOFFMANN-LA ROCHE AG 101
HOSPIRA INC. 101
JENKEN BIOSCIENCES INC. 102
JOHNSON and JOHNSON 102
MELIOR PHARMACEUTICALS INC 103
MERCK and CO. INC. 103
MYLAN PHARMACEUTICALS INC. 104
NOVARTIS AG 105
PAR PHARMACEUTICAL INC. 105
PFIZER INC. 106
SANDOZ 107
SANOFI 107
SOM BIOTECH SL 108
SOSEI GROUP LTD. 108
TAKEDA PHARMACEUTICALS U.S.A. INC. 109
TEVA PHARMACEUTICAL INDUSTRIES LTD. 109
UCB 110
ZYDUS CADILA GROUP 111
CHAPTER 10 APPENDIX I: ABBREVIATIONS 113

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH
2020 ($ MILLIONS) 8
TABLE 1 COMPARISON OF CHEMICALLY SYNTHESIZED DRUGS AND BIOLOGIC DRUGS 12
TABLE 2 EVOLUTION OF DRUG PRODUCTS 13
TABLE 3 DIFFERENCES IN NOVEL DRUG DEVELOPMENT AND DRUG REPURPOSING 21
TABLE 4 COMMON REPOSITIONED DRUGS THAT ARE MARKET APPROVED OR
UNDERGOING RESEARCH 25
TABLE 5 MARKET APPROVALS OF REPURPOSED DRUGS, 2010 TO APRIL 2015 29
TABLE 6 RECALLS OF REPURPOSED DRUGS, 2010 TO APRIL 2015 31
TABLE 7 SAFETY ALERTS FOR REPURPOSED DRUGS 32
TABLE 8 MERGERS AND ACQUISITIONS OF MAJOR PHARMACEUTICAL COMPANIES,
2010 TO APRIL 2015 36
TABLE 9 GLOBAL MARKET FOR REPURPOSED DRUGS BY REGION, THROUGH 2020 ($
MILLIONS) 46
TABLE 10 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%) 47
TABLE 11 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION, THROUGH
2020 ($ MILLIONS) 50
TABLE 12 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014
(%) 51
TABLE 13 TYPES OF CENTRAL NERVOUS SYSTEM DISORDERS 52
TABLE 14 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CENTRAL
NERVOUS SYSTEM DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 53
TABLE 15 TYPES OF CARDIOVASCULAR DISORDERS 55
TABLE 16 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR CARDIOVASCULAR
DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 56
TABLE 17 TYPES OF CANCER-DEPENDING ON THE TISSUE OF ORIGIN 58
TABLE 18 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR ONCOLOGY
DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 60
TABLE 19 TYPES OF AUTOIMMUNE DISEASES 61
TABLE 20 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR AUTOIMMUNE
DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 63
TABLE 21 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND
OTHER DISORDERS BY REGION, THROUGH 2020 ($ MILLIONS) 67
TABLE 22 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, THROUGH 2020 ($
MILLIONS) 69
TABLE 23 GLOBAL MARKET FOR REPURPOSED DRUGS BY APPLICATION SITE
THROUGH 2020 ($ MILLIONS) 72
TABLE 24 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
CENTRAL NERVOUS SYSTEM DISORDERS, 2014 74
TABLE 25 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%) 75
TABLE 26 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
AUTOIMMUNE DISORDERS, 2014 77
TABLE 27 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%) 77
TABLE 28 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
ONCOLOGY DISORDERS, 2014 78
TABLE 29 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR ONCOLOGY, 2014 79
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
CARDIOVASCULAR DISORDERS, 2014 80
TABLE 31 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR CARDIOVASCULAR DISORDERS, 2014 81
TABLE 32 LEADING MANUFACTURES/SUPPLIERS OF REPURPOSED DRUGS FOR
METABOLIC DISORDERS, 2014 82
TABLE 33 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR METABOLIC DISORDERS, 2014 82
TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF REPURPOSED DRUGS FOR
OTHER DISORDERS, 2014 83
TABLE 35 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR OTHER DISORDERS, 2014 84
TABLE 36 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015 88
TABLE 37 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015 88
TABLE 38 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015 89
TABLE 39 PATENTS BY COUNTRY, 2010 TO APRIL 2015 (NO/%) 90
TABLE 40 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015 91

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION,
2013-2020 ($ MILLIONS) 8
FIGURE 1 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY REGION,
2013-2020 ($ MILLIONS) 46
FIGURE 2 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY REGION, 2014 (%) 47
FIGURE 3 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION,
2013-2020 ($ MILLIONS) 50
FIGURE 4 GLOBAL MARKET SHARES OF REPURPOSED DRUGS BY APPLICATION, 2014
(%) 51
FIGURE 5 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR CENTRAL
NERVOUS SYSTEM DISORDERS BY REGION, 2013-2020 ($ MILLIONS) 54
FIGURE 6 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR
CARDIOVASCULAR DISORDERS BY REGION, 2013-2020 ($ MILLIONS) 56
FIGURE 7 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR
ONCOLOGY DISORDERS BY REGION 2013-2020 ($ MILLIONS) 60
FIGURE 8 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS USED FOR
AUTOIMMUNE DISORDERS BY REGION, 2013-2020 ($ MILLIONS) 64
FIGURE 9 GLOBAL MARKET FOR REPURPOSED DRUGS USED FOR METABOLIC AND
OTHER DISORDERS BY REGION, 2013-2020 ($ MILLIONS) 67
FIGURE 10 GLOBAL MARKET FOR REPURPOSED DRUGS BY USAGE, 2013-2020 ($
MILLIONS) 69
FIGURE 11 GLOBAL MARKET TRENDS FOR REPURPOSED DRUGS BY APPLICATION
SITE 2013-2020 ($ MILLIONS) 72
FIGURE 12 MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF REPURPOSED
DRUGS FOR CENTRAL NERVOUS SYSTEM DISORDERS, 2014 (%) 76
FIGURE 13 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR AUTOIMMUNE DISORDERS, 2014 (%) 78
FIGURE 14 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR ONCOLOGY, 2014 (%) 79
FIGURE 15 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR CARDIOVASCULAR DISORDERS, 2014 (%) 81
FIGURE 16 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR METABOLIC DISORDERS, 2014 (%) 82
FIGURE 17 MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF REPURPOSED
DRUGS FOR OTHER DISORDERS, 2014 (%) 84
FIGURE 18 NUMBER OF PATENTS BY YEAR, 2010 TO APRIL 2015 88
FIGURE 19 NUMBER OF PATENTS BY COMPANY, 2010 TO APRIL 2015 89
FIGURE 20 NUMBER OF PATENTS BY COUNTRY, 2010 TO APRIL 2015 89
FIGURE 21 PATENT SHARES BY COUNTRY, 2010 TO APRIL 2015 (%) 90
FIGURE 22 NUMBER OF PATENTS BY ASSIGNEE TYPE, 2010 TO APRIL 2015 (NO. OF
PATENTS) 91

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.